Objective: To evaluate the safety and reactogenicity of a reduced-antigen-content combined
Diphtheria-Tetanus-Acellular Pertussis (dTpa) vaccine in Indian pre-school children …

Objective: To evaluate immunogenicity and reactogenicity of primary vaccination with
reduced-antigen-content diphtheria-tetanus-acellular pertussis (dTpa) or dTpa-inactivated …

Background: Due to the resurgence of pertussis, many countries have revised the pertussis
immunization schedules and recommended booster doses of pertussis component vaccine …

Abstract▲ Boostrix® US formulation (hereafter referred to as Tdap) is a formulation of
reduced-antigen, combined diphtheria-tetanus-acellular pertussis vaccine, adsorbed onto …

Reduced-antigen-content diphtheria-tetanus-acellular pertussis (dTpa) vaccine, Boostrix™,
is indicated for booster vaccination of children, adolescents and adults. The original prefilled …

Boostrix® is a three-pertussis component, combined, reduced-antigen content tetanus,
diphtheria, and acellular pertussis (Tdap) booster vaccine administered as a single …

There is increasing interest in prevention of pertussis in adults by vaccination, but little is
known about the duration of the antibody response to pertussis, diphtheria or tetanus in …

ABSTRACT Background: An acellular Pertussis (aP) vaccine containing recombinant
genetically detoxified Pertussis Toxin (PTgen), Filamentous Hemagglutinin (FHA) and …

Reduced-antigen, combined diphtheria, tetanus, and acellular pertactin-containing pertussis
vaccine (dTpa; Boostrix™) contains reduced quantities of the same toxoids/antigens found …

BACKGROUND: Increasing incidence of pertussis in adolescents and adults has stimulated
the development of safe and immunogenic acellular pertussis vaccines for booster …